Trends in Growth, Market Segmentation, and Competitive Strategies Influencing the Angina Market

The angina market is set to experience significant growth over the coming years as advancements in cardiovascular care continue to evolve. With increasing demand for tailored treatment approaches and innovative technologies, the industry is positioned for notable expansion by 2030. Here's an in-depth look at the market's size, driving factors, leading companies, and emerging trends shaping its future.

Projections for Angina Market Size Expansion by 2030
The angina market is projected to reach a value of $14.84 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.3%. This steady rise is fueled by a variety of factors, including an increased focus on personalized cardiovascular therapies and the growing implementation of minimally invasive cardiac interventions. Additionally, the wider use of digital cardiac monitoring technologies and the expansion of preventive cardiology programs are playing crucial roles. Breakthroughs in cardiovascular drug development further support this upward trajectory. Market trends expected to influence growth include a greater adoption of combination drug treatments, enhanced reliance on long-acting nitrates, stronger emphasis on preventive cardiac care, expansion in interventional treatment options, and a renewed focus on lifestyle modifications and risk management.

Download a free sample of the angina market report:
https://www.thebusinessresearchcompany.com/report/angina-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Companies Leading the Angina Market Landscape
The angina market features several prominent players driving innovation and growth. Among these are Pfizer Inc., Bayer AG, AstraZeneca PLC, Merck & Co Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Otsuka Pharmaceutical Co Ltd, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Abbott Laboratories, Daiichi Sankyo Company Ltd, Takeda Pharmaceutical Company Limited, Cipla Limited, Sun Pharmaceutical Industries Ltd, Zydus Cadila Healare Ltd, Astellas Pharma Inc., Amarin Corporation, and Torrent Pharmaceuticals Ltd.

Notably, in March 2024, Novo Nordisk, based in Denmark, acquired Cardior Pharmaceuticals for $1.10 billion (€1.025 billion). This strategic move aims to strengthen Novo Nordisk's cardiovascular pipeline by incorporating Cardior's RNA-based therapeutics, particularly CDR132L, which is currently in Phase II clinical trials for heart failure treatment. Cardior Pharmaceuticals, a Germany-based company, is known for its work with angiotensin-converting enzyme inhibitors.

The angina market is set to experience significant growth over the coming years as advancements in cardiovascular care continue to evolve. With increasing demand for tailored treatment approaches and innovative technologies, the industry is positioned for notable expansion by 2030. Here's an in-depth look at the market's size, driving factors, leading companies, and emerging trends shaping its future.

Projections for Angina Market Size Expansion by 2030
The angina market is projected to reach a value of $14.84 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.3%. This steady rise is fueled by a variety of factors, including an increased focus on personalized cardiovascular therapies and the growing implementation of minimally invasive cardiac interventions. Additionally, the wider use of digital cardiac monitoring technologies and the expansion of preventive cardiology programs are playing crucial roles. Breakthroughs in cardiovascular drug development further support this upward trajectory. Market trends expected to influence growth include a greater adoption of combination drug treatments, enhanced reliance on long-acting nitrates, stronger emphasis on preventive cardiac care, expansion in interventional treatment options, and a renewed focus on lifestyle modifications and risk management.

Download a free sample of the angina market report:
https://www.thebusinessresearchcompany.com/report/angina-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Key Companies Leading the Angina Market Landscape
The angina market features several prominent players driving innovation and growth. Among these are Pfizer Inc., Bayer AG, AstraZeneca PLC, Merck & Co Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Otsuka Pharmaceutical Co Ltd, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Abbott Laboratories, Daiichi Sankyo Company Ltd, Takeda Pharmaceutical Company Limited, Cipla Limited, Sun Pharmaceutical Industries Ltd, Zydus Cadila Healare Ltd, Astellas Pharma Inc., Amarin Corporation, and Torrent Pharmaceuticals Ltd.

Notably, in March 2024, Novo Nordisk, based in Denmark, acquired Cardior Pharmaceuticals for $1.10 billion (€1.025 billion). This strategic move aims to strengthen Novo Nordisk's cardiovascular pipeline by incorporating Cardior's RNA-based therapeutics, particularly CDR132L, which is currently in Phase II clinical trials for heart failure treatment. Cardior Pharmaceuticals, a Germany-based company, is known for its work with angiotensin-converting enzyme inhibitors.

Factors Contributing to Positive Growth Trends in the Angina Market
Innovation in medical device technology is playing a vital role in advancing the angina market. One area gaining traction is the development of DNA-based wearable hormone patches that facilitate non-invasive, real-time hormone monitoring. These patches employ DNA-derived sensors to detect hormone levels in interstitial fluid, enabling users to track fluctuations without the need for invasive blood tests. Such technology is particularly valuable for fertility tracking and broader hormonal health management.

For instance, in February 2025, UK-based biotech firm Level Zero Health Inc. secured $6.9 million in an oversubscribed pre-seed funding round to develop the world's first continuous hormone monitoring patch. This DNA-based wearable device tracks hormones including cortisol, progesterone, estrogen, and testosterone through an arm-worn patch. It provides real-time insights into hormonal changes, supporting fertility management, hormonal health, and remote clinical monitoring. Initially targeting B2B applications such as fertility clinics and endocrine treatment centers, Level Zero Health plans to eventually expand into consumer wellness markets, offering a less invasive alternative to frequent clinic visits.

Key Segments Driving Growth in the Angina Market
This report divides the angina market into several major segments to better understand growth drivers:

1) By Type: Angina Pectoris, Unstable Angina, Prinzmetal Angina, and Other Types
2) By Treatment: Lifestyle Changes, Medications, Angioplasty and Stenting, Coronary Bypass Surgery, and Other Treatments
3) By Drug Class: Beta Blockers, Nitrates and Calcium Channel Blockers, Angiotensin-Converting Enzyme Inhibitors, and Other Drug Classes
4) By Application: Clinics, Hospitals, and Other Settings

Further subcategories detail important distinctions within these segments. For Angina Pectoris, subtypes include Stable Angina, Chronic Stable Angina, Effort-Induced Angina, and Variant or Microvascular Angina. Unstable Angina covers Acute Unstable Angina, Pre-Infarction Angina, and Rest Angina. Prinzmetal Angina is broken down into Vasospastic Angina, Coronary Artery Spasm-Induced Angina, and Variant Angina. Other Types include Nocturnal Angina, Post-Infarction Angina, Angina with Silent Myocardial Ischemia, and Angina caused by Aortic Stenosis or Valve Disease.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.